Dr. Ben Sessa

(Part three of a four-part series) As for ketamine-assisted therapy, biotech psychedelics company Awakn Life Sciences (OTC: AWAKNF) offers two distinct protocols. One is called KARE (Ketamine in the Reduction of Alcoholic Relapse) and is specific to alcohol use disorder, while the other, KAP (...

(Part two of a four-part series, see part one here) Dr. Ben Sessa, cofounder and head of psychedelic medicine at Awakn Life Sciences (OTC: AWKNF) explained that scientific evidence shows ketamine creates neurogenesis: “You actually have growth of nervous tissue. You can...

Global Developments in Germany, Canada and Brazil Germany has approved a large phase 2b study on psilocybin for treatment-resistant depression. Dr. Gerhard Gründer, of the Central Institute of Mental Health Mannheim, will lead the study alongside the Department of Psychiatry and...